Novo Nordisk A/s

Massachusetts Institute of Technology

The Brigham and Women's Hospital, Inc.

Andreas Vegge

Philip Jonas Sassene

Robert Samuel Langer

Marie-Ange Buyse

Carlo Giovanni Traverso

Soren Steffensen

Frantisek Hubalek

Alex G Abramson

Jesper Peter Windum

Morten Revsgaard Frederiksen

Robert S Langer, Jr

Brian Mouridsen

Mathias Norrman

Brian Jensen

Birgitte Schjellerup Wulff

Simon Bjerregaard

Jorrit Jeroen Water

Birgitte Nissen

Mikkel Oliver Jespersen

Jais Rose Bjelke

Thomas Egebjerg

Evelyn De Tavernier

Per J Greisen

Mette Poulsen

Jacob Lund

Ulrik Lytt Rahbek

Mikkel Wennemoes Hvitfeld Ley

Xiaoya Lu

Daniele Granata

Simone Fulle

Susanne Scheele

Sassene Philip Jonas

Water Jorrit Jeroen

Søren ØStergaard

Betty Lomstein Pedersen

Susanne SCHÉELE

Jesper Windum

Rahbek Ulrik Lytt

The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.

Highly potent ISVD compounds capable of substituting for FVIII(A)

Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject) such as a liquid pharmaceutical agent. In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component is associated with a self-actuating component. For example, the self-righting article may comprise a self-actuating component configured, upon exposure to a fluid, to release the tissue interfacing component from the self-righting article.

Systems and methods for liquid injection

The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.

Solid glp-1 derivative compositions for oral administration

Growing community of inventors

Frederiksberg, Denmark

Andreas Vegge